Skip to main content

Table 5 Unadjusted multilevel mixed-effects logistic regression analyzing the relationship between disease-specific features and oral variables, with the dichotomized outcome variable presence of caries (d1-5fs/D1-5FS > 0 or = 0) in children and adolescents with juvenile idiopathic arthritis (JIA)

From: Dental caries in children and adolescents with juvenile idiopathic arthritis and controls: a multilevel analysis

 

Respondents, n

OR (95% CI)

p value

JIA category

 Oligoarthritis persistent

77

1

0.29*

 Systemic arthritis

7

0.93 (0.17–5.17)

0.94

 Oligoarthritis extended

20

1.88 (0.65–5.43)

0.24

 Polyarthritis, RF positive

4

3.07 (0.38–24.83)

0.29

 Polyarthritis, RF negative

49

2.19 (0.99–4.85)

0.05

 Psoriatic arthritis

8

2.99 (0.67–13.34)

0.15

 Enthesitis-related arthritis

23

0.64 (0.21–1.96)

0.44

 Undifferentiated arthritis

31

0.84 (0.31–2.26)

0.74

Steroids, ongoing

 No steroids ongoing

215

1

Ref

 Steroids ongoing

4

2.31 (0.26–20.58)

0.45

Steroids, ever used

   

 No steroids ever used

172

1

Ref

 Steroids ever used

47

1.30 (0.63–2.71)

0.48

DMARDs, ongoing

 No sDMARDs nor bDMARDs ongoing

73

1

0.78*

 sDMARDs, but no bDMARDs ongoing

60

0.82 (0.37–1.79)

0.61

 bDMARDs ongoing (with or without sDMARDs)

86

1.06 (0.52–2.16)

0.88

DMARDs, ever used**

 No sDMARDs nor bDMARDs ever used

51

1

0.61*

 sDMARDs, but no bDMARDs ever used

79

1.32 (0.58–3.01)

0.50

 bDMARDs ever used (with or without sDMARDs)

89

1.48 (0.66–3.31)

0.34

Age at JIA onset

 ≤ 6 years

110

1

Ref

 > 6 years

109

1.66 (0.90–3.07)

0.11

Disease duration

 ≤ 5 years

117

1

Ref

 > 5 years

102

1.35 (0.73–2.48)

0.34

Remission status***

 Inactive disease/remission on/off medication

130

1

ref

 Continued activity/flare

89

1.16 (0.63–2.16)

0.63

MDgloVAS

 VAS = 0

140

1

Ref

 VAS > 0

79

1.26 (0.67–2.37)

0.48

PRgloVAS****

 VAS = 0

106

1

Ref

 VAS > 0

108

1.24 (0.67–2.29)

0.49

CHAQ hygiene item tooth brushing****

 Without any difficulty

203

1

Ref

 With some/much difficulty/unable to do/not applicable

11

1.03 (0.26–4.09)

0.96

Jaw

 Mandible

 

1

Ref

 Maxilla

 

1.02 (0.79–1.32)

0.86

Side

   

 Right side

 

1

Ref

 Left side

 

1.14 (0.88–1.46)

0.33

Surface

 A: Buccal

 

1DE

< 0.01*

 B: Distal

 

0.82 (0.49–1.38)DE

0.46

 C: Lingual

 

0.74 (0.44–1.26)DE

0.27

 D: Mesial

 

2.44 (1.56–3.82)ABCE

< 0.01

 E: Occlusal

 

6.30 (4.11–9.66)ABCD

< 0.01

ICC

 

0.47

 
  1. RF, Rheumatoid Factor; sDMARDs, synthetic disease-modifying antirheumatic drugs; bDMARDs, biologic disease-modifying antirheumatic drugs; MDgloVAS, Physician's global assessment of disease activity; PRgloVAS, Patient's global assessment of overall wellbeing; CHAQ, Childhood Health Assessment Questionnaire; ICC, intra-class correlation coefficient
  2. *Overall p value. Surfaces statistically significant in post-hoc analyses are marked with the superscript letters of the pertinent surfaces. Scheffe adjusted p values in post-hoc analyses p < 0.05. For ‘JIA category’, ‘other medication ongoing and ever used’, and post- hoc analysis showed no differences (all p values > 0.05). **Include both previously used and ongoing medication. ***Disease activity according to Wallace and the American College of Rheumatology (ACR) provisional criteria [43, 44]. ****Responses (n = 5) are missing
Back to article page

BMC Oral Health

ISSN: 1472-6831

Contact us